Lataa...
Population exposure–safety analysis of cediranib for Phase I and II studies in patients with cancer
AIMS: A multistudy analysis of cediranib, a potent, selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR‐1, ‐2 and ‐3), was conducted to establish population exposure–safety models for the relationship of cediranib exposure to the safety endpoints, diastolic and systo...
Tallennettuna:
| Julkaisussa: | Br J Clin Pharmacol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5867133/ https://ncbi.nlm.nih.gov/pubmed/29274100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13495 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|